日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / The Third China International Import Expo

Anti-COVID products, technologies stand out at Shanghai event

By ZHOU WENTING in Shanghai | China Daily | Updated: 2020-11-05 09:38
Share
Share - WeChat
Employees rest at the public health and epidemic prevention exhibition zone of the third CIIE in Shanghai on Tuesday. [Photo/Xinhua]

Medical industry exhibitors at the third China International Import Expo in Shanghai are showcasing the latest products that highlight innovation and collaboration as key to the world's COVID-19 combat.

Industry observers said this is significant as some countries are experiencing the second wave of the pandemic, and could benefit from products that are on display at the CIIE.

Some 48 companies are exhibiting their blockbuster products and technologies related to the prevention and treatment of the novel coronavirus pneumonia.

Their products stand out in the public health and epidemic prevention exhibition zone that has been added to the expo this year.

The products and technologies reveal tireless efforts of the medical industry to contain the spread of the novel coronavirus and facilitate an optimized defense system against it.

Protective suits and disinfectants for prevention, test kits and CT devices for testing, and ventilators and extracorporeal membrane oxygenation machines for treatment are on display at the 12,000-square-meter zone.

The initial planned area for this section of the expo was 2,000 square meters but was expanded multiple times, following a high level of enthusiasm among exhibitors, according to the CIIE organizer.

Tocilizumab, a star immunosuppressant from Roche Pharma, which has been found to reduce the need for mechanical ventilation among acute COVID-19 patients, is among the exhibits. In early March, the National Health Commission included Tocilizumab in the country's COVID-19 diagnosis and treatment plan.

Roche said research results showed COVID-19 patients who received the drug plus standard treatment were 44 percent less likely to progress to mechanical ventilation or death compared with other patients receiving placebo plus standard treatment.

Roche donated the drug worth around 14 million yuan ($2.1 million) to support medical institutions across China, particularly in Wuhan, Hubei province, when the city was hit hard by the epidemic.

Takeda, a Japanese biopharmaceutical company, said it has joined hands with world-leading plasma companies to set up the COVID-19 Plasma Alliance to help develop a potential plasma-derived therapy for acute cases.

Takeda said an experimental therapy is now being tested in a phase-III clinical trial. If successful, the alliance's hyperimmune intravenous immunoglobulin may become one of the earliest treatment solutions for hospitalized, adult COVID-19 patients.

In parallel research, Takeda is also testing four products that could be effective against COVID-19.

"COVID-19 reminds us that public health matters for global prosperity, and cross-border collaboration is essential to fight against the pandemic," said Sean Shan, president of Takeda China. "In such a context, the (third) CIIE offers a new ecosystem to bolster global cooperation in innovation."

AbbVie, a debutant at the CIIE, is exhibiting a potential antibody therapy that is being jointly researched and developed with a US-based pharmaceutical company, Harbour BioMed, a Chinese biotech company, and two universities in the Netherlands-Utrecht University in Utrecht and Ernakulam Medical Centre in Rotterdam. The antibody therapy, if proven successful, would prevent as well as treat COVID-19.

Fosun Health is exhibiting an experimental COVID-19 vaccine it jointly developed with Germany's BioNTech, a biotech company specializing in messenger RNA, or mRNA. In July, the mRNA vaccine candidate was approved in China for stage-I clinical trial, which will be kicked off in Taizhou city, Jiangsu province.

"By Sept 4, all 144 participants in the trial had completed taking the vaccine twice and were responding well," Fosun Health said in a news release.

Another vaccine candidate jointly developed by BioNTech and Pfizer has started stage-II B and stage-III multicenter clinical trials in countries including the United States since July. On Sept 12, Pfizer said it will expand the number of participants in its large-scale trials from 30,000 to 44,000.

Compared with traditional vaccines, mRNA candidates are said to be more efficient in research and development, offer better safety, and their production can be swiftly scaled up.

Experts said they believed such vaccines are suitable during sudden outbreaks of epidemics like COVID-19.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 成人嗯啊视频在线观看 | 国产激情91久久精品导航 | 视频毛片 | 午夜在线看| 国产亚洲综合久久 | 一级做a爰性色毛片免费 | 欧美视频性 | 高清亚洲| 精品卡1卡二卡3卡 | 欧美一区二区精品 | 99只有精品| 色永久| 国产成人精品久久亚洲高清不卡 | 波多野结衣一区二区三区在线观看 | 国产乱码精品一区二区三区中文 | 涩涩97| 成人在线综合网 | 国产精品玖玖玖在线观看 | 色男人天堂 | 狠狠狠狠操 | 亚洲高清在线看 | 国产成人综合一区二区三区 | 欧美一级片免费看 | 日本在线网站 | 国产精品视频第一区二区三区 | 国产精品xxxav免费视频 | 国产一区免费 | 色爱av| 日本亚洲精品色婷婷在线影院 | caoporn视频| 久久精品免费观看 | 国产三级在线观看视频 | 国产精品久久人妻无码网站蜜臀 | 久久精品av麻豆的观看方式 | 国产一级黄色网 | 亚洲免费视频一区 | 日韩亚洲一区二区 | 久久久青青草 | 亚洲国产成人久久综合碰 | 国产福利合集 | 国产精品成人国产乱一区 |